AI in Life Science Analytics Market Report 2025

The AI in life science analytics market size has grown rapidly in recent years. It will grow from $2.27 billion in 2024 to $2.65 billion in 2025 at a compound annual growth rate (CAGR) of 16.7%. The growth in the historic period can be attributed to research and development funding, regulatory changes, drug discovery challenges, healthcare digitization, patient-centric care.

The AI in life science analytics market size is expected to see rapid growth in the next few years. It will grow to $5.34 billion in 2029 at a compound annual growth rate (CAGR) of 19.1%. The growth in the forecast period can be attributed to drug repurposing opportunities, real-world evidence adoption, genomics advancements, value-based care models, and telemedicine expansion. Major trends in the forecast period include augmented reality (AR) in healthcare, digital biomarkers analysis, continuous learning algorithms, remote patient monitoring, and personalized medicine.

The growing adoption of AI is anticipated to drive the growth of AI in the life science analytics market in the coming years. Artificial intelligence (AI) is defined as a field that integrates datasets and computer science to facilitate problem-solving. It also includes processes such as machine learning and deep learning, which are often associated with artificial intelligence. In life science analytics, AI serves various functions, including drug discovery, clinical trials, medical diagnostics, patient monitoring, and personalized medicine. For example, in 2022, a report from International Business Machines Corporation, a US-based technology company, indicated that 35% of companies worldwide are currently utilizing AI, while 42% are planning to incorporate AI into their processes and applications. Consequently, the increasing adoption of AI is propelling the growth of AI in the life science analytics market.

The increase in healthcare expenditure is expected to further boost the growth of AI in the life science analytics market in the coming years. Healthcare expenditure refers to the total amount spent on healthcare goods and services over a specific timeframe, covering various costs associated with medical treatment and public health initiatives. As healthcare organizations increasingly focus on data-driven decision-making and advanced analytics for research, diagnosis, and personalized treatment, the integration of artificial intelligence (AI) into life science analytics becomes essential. AI technologies, including machine learning and predictive analytics, can streamline processes, accelerate drug discovery, and improve patient outcomes. The growing financial investment in healthcare infrastructure and technology is likely to accelerate the adoption of AI-driven analytics. For instance, a report from the CIHI, a Canadian Institute for Health Information, projected that total health spending in Canada would increase by 0.8%, from $328 billion in 2021 to $331 billion in 2022. Therefore, the rising healthcare expenditure is driving the growth of AI in the life science analytics market.

Technological advancement emerges as a pivotal trend gaining momentum in the AI segment of the life science analytics market. Key industry players are adopting new technologies to maintain their market standing. For instance, in October 2023, BioLizard unveiled the AI-empowered BioVerse platform, aimed at facilitating data-driven research and development for the global life sciences community. This user-friendly platform, encompassing applications such as Bio|Reflect, Pro|Biome, and Bio|Mx, targets scientists in biotech and pharma fields, offering tailored solutions for data-driven outcomes. BioVerse's goal is to support data-driven discovery, preclinical, translational, and clinical R&D processes through AI-driven solutions, showcasing BioLizard's commitment to innovation in the life sciences industry.

Major players in the Artificial Intelligence (AI) sector for life sciences analytics are innovating new offerings aimed at automating insights, empowering professionals to make smarter, faster, and more informed data-driven decisions. In October 2023, WhizAI, a US-based software company, unveiled ExplAIn, an AI-driven analytics solution tailored for life sciences analysts and power users. This cutting-edge platform leverages generative AI to automate insights, facilitating quicker and more intelligent decision-making processes. Its capability to manage extensive datasets allows real-time responses to intricate queries.

in February 2023, Envision Pharma Group (Envision), a US-based technology company, made a strategic acquisition by procuring OKRA.ai for an undisclosed sum. This acquisition fortifies Envision's technological prowess, granting clients access to advanced AI tools that expedite decision-making processes, thereby enhancing product trajectories and supporting improved patient outcomes. OKRA.ai, a UK-based technology company specializing in AI solutions, excels in commercialization, real-world evidence, data analytics, and pharmaceutical and life sciences-related medical and pricing domains.

Major companies operating in the AI in life science analytics market include Indegene Limited, International Business Machines Corporation, IQVIA Holdings Inc., Lexalytics Inc., Databricks Inc., SAS Institute Inc., Sisense Inc., Sorcero Atomwise Inc., Microsoft Corporation, NVIDIA Corporation, Oracle Corporation, NuMedii Inc., Enlitic Inc., Apixio Inc., AiCure LLC, Google LLC, Amazon Web Services Inc., Accenture, Cognitivescale, CloudMinds, Ayasdi, BioSymetrics, Cloud Pharmaceuticals, Cyrcadia Health, Freenome, GNS Healthcare, Insilico Medicine, MedWhat, PathAI, Recursion Pharmaceuticals, Sophia Genetics, Veracyte Inc.

North America was the largest region in the AI in life science analytics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the AI in life science analytics market report during the forecast period. The regions covered in the ai in life science analytics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ai in life science analytics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Artificial Intelligence (AI) in life sciences analytics involves the use of technology to analyze data and transform unstructured information into actionable insights. This technology plays a crucial role in various life sciences applications, including conducting clinical trials, facilitating new drug discoveries, and enhancing the precision and accuracy of disease diagnoses.

The main components of the AI in life sciences analytics market include software, hardware, and services. Software encompasses applications, scripts, data, programs, or sets of instructions that operate computers and execute specific tasks in the life sciences sector. These software applications are utilized for data management, quality management, sales enablement, drug discovery, and other purposes. They can be deployed on-premises or in the cloud and are applied in various applications such as research and development, sales and marketing support, supply chain analytics, and more. The end-users of AI in life sciences analytics include medical devices, pharmaceuticals, biotechnology, and other related industries.

The AI in life science analytics market research report is one of a series of new reports that provides AI in life science analytics market statistics, including AI in life science analytics industry global market size, regional shares, competitors with an AI in life science analytics market share, detailed AI in life science analytics market segments, market trends, and opportunities, and any further data you may need to thrive in the AI in life science analytics industry. This AI in life science analytics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The AI in the life science analytics market includes revenues earned by entities by providing predictive analytics, prescriptive analytics, and cognitive analytics services. The market value includes the value of related goods sold by the service provider or included within the service offering. AI in the life science analytics market also includes sales of target identification, target validation, and clinical decision support hardware. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.